Spherex

06/01/1995 - "[Liver tumor targeting of drugs: Spherex, a vascular occlusive agent]."
01/01/1993 - "[Chemoembolization of liver tumors (VX-2) using lyophilized Spherex]."
04/01/1992 - "Accordingly, the AUC values were significantly lower too (AUC = 28.6 micrograms/ml.h with Spherex and 39.7 micrograms/ml.h without Spherex), thus leading to a lower systemic bioavailability of the drug and a higher local bioavailability in the tumor region. "
06/01/1986 - "Ten patients with primary or secondary liver tumor were subjected to preoperative angiographic mapping of the hepatic circulation, combined with infusion of microspheres (Spherex Infusion). "
04/01/1997 - "Spherex (degradable starch microspheres) chemo-occlusion--enhancement of tumor drug concentration and therapeutic efficacy: an overview."

07/01/2005 - "[Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature]."
01/01/1998 - "[Significant modification of the hyperthermic effect by starch microspheres (Spherex) of laser-induced hypertheria in the rat liver metastasis model]."
01/01/1998 - "This experimental study in an animal liver metastasis model (adenocarcinoma) investigated whether the "cooling effect" can be eliminated by temporary embolization with starch microspheres (Spherex) and the hyperthermic efficiency was improved. "
03/01/1991 - "The influence of the vasopressin-pro-drug glycylpressine (GP) and of a chemoembolisation with Spherex starch-particles (SP) on the availability of mitomycin (CAS 50-07-7, mitomycin C, MMC) was investigated in 30 patients with liver metastases, MMC administration was performed after blocking of the common hepatic artery by different concentrations of SP and after different time-intervals of GP. "
04/01/2002 - "TACE, using a combination of mitomycin C, dexamethasone and interferon-alpha2b mixed with Spherex((R)), followed by oxaliplatin, FA and 5-FU, appears to be an effective and feasible treatment option in the case of liver metastasis of CRC refractory to standard systemic chemotherapy. "

01/01/1998 - "This experimental study in an animal liver metastasis model (adenocarcinoma) investigated whether the "cooling effect" can be eliminated by temporary embolization with starch microspheres (Spherex) and the hyperthermic efficiency was improved. "

04/01/1997 - "Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis."
04/01/1997 - "Patients with advanced-stage unresectable hepatocellular carcinoma (HCC) were treated with intrahepatic arterial doxorubicin 30 mg/m2 plus escalating doses of cisplatin up to 100 mg/m2 in conjunction with rapid bolus injection of Spherex (degradable starch microspheres; Kabi Pharmacia, Lund, Sweden) into the hepatic artery, until slowing or reversal of blood flow. "

06/01/1995 - "Although the rate of side effects exhibited, including pain, digestive symptoms and fever, has been significantly higher in combination with Spherex, myelosuppression indicated by abnormal fluctuations in leukocyte and platelet counts was found to be greater with administration of MMC alone, suggesting its value as an effective future therapy for metastatic hepatic carcinoma. "
02/01/1987 - "The effectiveness of arterial embolization using DSM (Degradable Starch Microspheres, Spherex, Sweden) combined with hyperthermia were investigated in the treatment of VX2 carcinoma in rabbits and also in human hepatic tumors. "
03/01/1991 - "During a period of nine months, fifteen patients with extensive hepato-cellular carcinomas were subjected to palliative arterial chemo-embolisation using doxorubicin and cisplatin in an emulsion with Lipiodol and/or Spherex particles. "